NSE · LYKALABS
Lyka Labs Ltd.
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹28 Cr with net profit ₹-30 Cr — a -106.21% net margin, versus -7.6% the period before.
Shareholding
As of 2026-06-30
- Promoter58.45%
- Public40.72%
- FII0.17%
- DII0.66%
29,369 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 2.75× from low to high.
Risk flags
Derived from disclosed data
- Under exchange surveillance — ESM · ESM 1. Trading may carry price bands, periodic call auction or higher margins.
Peer comparison
Pharmaceuticals - Indian - Bulk Drugs & Formln · ranked #60 of 102 by market cap · medians across 50 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | ₹4,77,444 Cr | 38.42 | 5.71 | 13.74% | 19.72% |
| Cipla Ltd. | ₹1,19,101 Cr | 214.6 | 3.46 | 11.27% | 14% |
| Zydus Lifesciences Ltd. | ₹1,11,990 Cr | 20.62 | 4.13 | 18.59% | 18.86% |
| Lupin Limited | ₹1,11,885 Cr | 70.26 | 4.98 | 23.76% | 19.4% |
| Mankind Pharma Limited | ₹1,07,077 Cr | 192.91 | 6.57 | 11.74% | 13.4% |
| Laurus Labs Limited | ₹96,235 Cr | 344.55 | 18.14 | 16.77% | 13.05% |
| Dr Reddys Laboratories Ltd. | ₹95,344 Cr | 431.06 | 2.52 | 0.11% | 0.12% |
| Aurobindo Pharma Ltd. | ₹92,388 Cr | 100.3 | 2.44 | 9.25% | 10.5% |
| Biocon Ltd. | ₹69,942 Cr | 546.2 | 2.06 | 1.14% | 2.3% |
| Alkem Laboratories Ltd. | ₹67,823 Cr | 286.92 | 4.91 | 16.66% | 15.65% |
| Lyka Labs Ltd.(this company) | ₹214 Cr | 45.07 | 2.31 | -10.86% | -7.82% |
AI analysis
AI-generated · google/gemini-2.5-flashLyka Labs Ltd. is listed on the Indian markets with a market capitalization of Rs 248 Cr. The company reported a revenue of Rs 140.73 Cr with a profit margin of -7.82%. Its 52-week high was Rs 121.44 and its 52-week low was Rs 44.1.
Positives
- +Revenue grew 24.6% to Rs 140.73 Cr.
- +Promoter holding of 58.16% in March 2026 is above 50%.
- +No promoter shares were reported as pledged as of March 2026.
Negatives
- −The company reported a negative profit margin of -7.82%.
- −Return on Equity (ROE) is negative at -10.86%.
- −Return on Capital Employed (ROCE) is negative at -6.04%.
- −Net profit in the latest quarter (Mar 2026) was negative at Rs -7.61 Cr.
- −The company is under the ESM (Enhanced Surveillance Mechanism) Stage 1.
Financial performance
Lyka Labs Ltd. reported revenue of Rs 140.73 Cr, representing a growth of 24.6%. The company's net profit for the year ending March 2025 was Rs 7.90 Cr, with earnings per share (EPS) of Rs 2.22. However, the latest quarterly results for March 2026 show a net loss of Rs -7.61 Cr on a revenue of Rs 28.03 Cr.
Profitability & returns
The company's profit margin stood at -7.82%. Its Return on Equity (ROE) was -10.86%, and Return on Capital Employed (ROCE) was -6.04%. For the year ending March 2025, EBITDA was Rs 13.39 Cr.
Balance sheet
The debt-to-equity ratio for Lyka Labs Ltd. was 0.44. The book value per share is Rs 25.68. The company has not declared any dividend, resulting in a dividend yield of 0%.
Ownership & pledges
As of March 2026, promoters held 58.16% of the company's shares. Public shareholding was 40.88%, FIIs held 0.29%, and DIIs held 0.67%. Institutional holding was 0.95%. There were no promoter pledges reported for March 2026.
Regulatory & surveillance
The company is currently under the ESM (Enhanced Surveillance Mechanism) framework, categorized as ESM 1, with measures including "ESM" and "ESM".
Data as of — price: 2026-07-29 · financials: Mar 26 · shareholding: Jun 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.